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Abstract: The increasing demand for novel drug formulations has caused the introduction of
the supercritical fluid technology, CO2 in particular, into pharmaceutical technology as a method
enabling the reduction of particle size and the formation of inclusion complexes and solid dispersions.
In this paper, we describe the application of scCO2 in the preparation of binary systems containing
poorly soluble antiandrogenic drug bicalutamide and polymeric excipients, either Macrogol 6000 or
Poloxamer®407. The changes in the particle size and morphology were followed using scanning
electron microscopy and laser diffraction measurements. Differential scanning calorimetry was
applied to assess thermal properties, while X-ray powder diffractometry was used to determine the
changes in the crystal structure of the systems. The dissolution of bicalutamide was also considered.
Binary solid dispersions were further compressed, and the attributes of tablets were assessed.
Tablets were analyzed directly after manufacturing and storage in climate chambers. The obtained
results indicate that the use of supercritical CO2 led to the morphological changes of particles and the
improvement of drug dissolution. The flowability of blends containing processed binary systems
was poor; however, they were successfully compressed into tablets exhibiting enhanced drug release.
Keywords: Bicalutamide; Poloxamer® 407; Macrogol 6000; supercritical carbon dioxide; solid
dispersions; dissolution rate; amorphization
1. Introduction
The growing number of active pharmaceutical ingredients (APIs) are characterized by poor water
solubility. Currently, more than 70% of APIs under development are considered as poorly water
soluble and almost 40% present in the pharmaceutical industry possesses aqueous solubility less than
100µg/mL. Most of them belong to the second class of the Biopharmaceutical Classification System (BCS).
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These compounds are characterized by low solubility and high intestinal membrane permeability [1].
Given that the oral bioavailability of active pharmaceutical ingredients depends on their solubility and/or
dissolution rate, many methods of solubility improvement have been developed [2]. They include
chemical modifications, such as prodrugs [3,4] or salt formation [5], physical processes as micronization
or polymorph transitions, as well as the preparation of drug-carrier systems, including solid dispersions
(SD) [6,7] and complexes with cyclodextrins [8–11]. Solid dispersions are defined as drug-carrier
systems in which a hydrophobic active pharmaceutical ingredient is either molecularly dispersed
in a hydrophilic matrix or exists as micro-fine crystals [12]. The matrix can be made from low
molecular weight compounds, or more frequently, hydrophilic polymers. They provide the dissolution
rate improvement, particle size reduction, reduction of agglomeration, wettability improvement
that are achieved by solid dispersion [13,14]. They possess different functional groups, molecular
weight, melting temperatures (Tm), and glass transition temperatures (Tg). They can be crystalline
(poly(vinyl alcohol)), semicrystalline (poly L-lactic acid), or amorphous (polyvinylpyrrolidone).
Moreover, each polymer is characterized by different abilities to maintain molecular dispersion of active
substances [15]. Drug-polymer solid dispersions are formed using evaporation methods, such as spray
drying, and melting methods, including extrusion. These techniques often require high temperatures,
which can influence the stability of the active substance, or high amounts of solvents, which may
increase product toxicity and affect the environment [16]. These undesirable effects can be avoided
by using supercritical fluid technology for solid dispersion preparation. The most commonly used
gas is carbon dioxide, which is a non-toxic, non-flammable and widely available substance. In the
supercritical state, i.e., above the critical temperature (31.4 ◦C) and pressure (74 bar), it is viscous and
permeable like gaseous substances, while the density is comparable with liquids. It can act as a solvent
and/or as a plasticizer for many substances. Also, it is easy to remove from the product after processing,
so it is possible to obtain a solvent-free product without a dedicated solvent removal process [16–19].
Currently, tablets are the most popular dosage form. This is due to the ease of administration,
neutral taste, appropriate stability and low cost of manufacturing [20–23]. Given that compression is an
integral part of tableting, the effect of applied the compression force on the physical stability of the drug
needs to be considered, especially in the case of the compounds undergoing mechanically induced
activation [24,25]. One of such is bicalutamide, a non-steroidal antiandrogen, which belongs to class II
of the Biopharmaceutics Classification System, exhibiting low aqueous solubility (below 5 µg/mL) and
high lipophilicity (logP = 2.92) [26]. Th drug undergoes polymorph transition (from physically stable
form I to metastable form II) or amorphization upon mechanical treatment as a consequence of a need
for the relaxation of stress field applied during milling [27,28]. Drug amorphization was previously
described upon milling and spray drying with polyviylpyrrolidone (PVP) [29,30]. Given that glassy
bicalutamide recrystallizes easily upon grinding or scratching, the effect of increased pressure on
physical stability needs to be investigated deeply. Although many papers describe the effect of
temperature and humidity on the stability of amorphous drugs, the effect of pressure applied to solid
dispersions during tableting was rarely described [31]. Also, only a few papers describe how the
tableting and storage of solid dispersions affect the dissolution performance of bicalutamide.
The polymers chosen for this study were polyethylene glycol (Macrogol 6000, PEG6000,) and
Poloxamer® 407 (PLX407). These excipients are commonly used for solid dispersion preparation due
to their solubilizing effects, surface adsorption, and wetting enhancement. Macrogols are widely used
as carriers due to their low melting point, fast solidification, and capability of forming solid drug
solutions [32,33]. However, the presence of a crystalline form may result in unstable formulations
and lower dissolution rates [32]. For some drug-active substances, the improvement in solubility
enhancement by Poloxamer is more efficient than by Macrogols [34]. Poloxamers, also called pluronics,
are amphiphilic block copolymers consisting of hydrophilic ethylene oxide blocks (EO) attached to a
central polypropylene oxide unit (PO) of hydrophobic character. They are widely used as carriers,
mostly due to a low melting point. Moreover, the differences in the solubility of the constituent blocks
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of poloxamer macromolecule lead to thermo-responsive self-assembly in an aqueous environment,
which is the additional advantage for solubility enhancement [35].
In our studies, we evaluated the use of the supercritical carbon dioxide (scCO2) method as a
way to obtain solid dispersions with bicalutamide, which were further (after mixing with excipients)
compressed into tablets. The effect of tableting and storage in both normal and accelerated conditions
was evaluated together with drug dissolution performance.
2. Materials and Methods
2.1. Materials
Bicalutamide (BCL, 99.3% purity, Hangzhou Hyper Chemicals Limited, Hangzhou, China) was
used as an active substance: molecular formula C18H14F4N2O4S, molecular weight 430.4 g/mol,
solubility in water 3.7 µg/mL, logP = 2.92, pKa = 12.6, melting point 196 ◦C. Macrogol 6000 (PEG6000,
Clariant, Muttenz, Switzerland): molecular formula H(OCH2CH2)nOH, average n = 100, nonionic
substance, melting point 65 ◦C, and Poloxamer® 407 (PLX407, BASF, Ludwigshafen am Rhein,
Germany), molecular formula HO(C2H4O)a(C3H6O)b(C2H4O)aH a = 101, b = 56; average molecular
weight 9840–14,600 g/mol, melting point 55 ◦C, freely soluble polymers were used as carriers.
Carbon dioxide (CO2; 99.99% purity, Pszczyna, Linde Gaz, Poland) was used as a supercritical
fluid. Sodium lauryl sulfate (SLS; 98.8% purity; BASF) was used to prepare dissolution medium.
Distilled water was used to prepare all the solutions. Cellulose microcrystalline (JRS Pharma, Rosenberg,
Germany), sodium starch glycolate (DFE Pharma, Goch, Germany) and magnesium stearate (Merck,
Darmstadt, Germany) were used as excipients to formulate tablets. All excipients used to formulate
tablets were of pharmaceutical grade.
2.2. Methods
2.2.1. Solid Dispersion Preparation Using Supercritical Carbon Dioxide (scCO2)
Bicalutamide and carriers, i.e., Macrogol 6000 or Poloxamer® 407, were mixed in a 1:1 weight
ratio and loaded into a high-pressure reactor BR-300 (Berghof Products + Instruments GmbH, Eningen
unter Achalm, Germany) equipped with a magnetic stirrer MR Hei-Standard (Heidolph Instruments,
Schwabach, Germany), a heating mantle and a CHY 700T thermometer (CHY Firemate Co., Tainan City,
Taiwan). To obtain supercritical conditions, carbon dioxide was pumped and compressed into a
high-pressure reactor by a syringe pump SFT-10 (Supercritical Fluid Technologies Inc., Newark, NJ, USA).
The process was conducted at 50 ◦C and 150 bar with Macrogol 6000 as a carrier, and at 60 ◦C and 160 bar
with Poloxamer®407. In both cases, the magnetic stirrer was set at 500 rpm. The process parameters
were monitored during the whole operation. The total mass of powder introduced into the high-pressure
reactor was equal to 2 g. After the process, solid dispersions were pulverized through 1.8 mm sieve.
2.2.2. Scanning Electron Microscopy (SEM)
The morphological characterization of the samples was conducted using a Phenom Pro desktop
electron microscope (Phenom World, Thermo Fisher Scientific, Waltham, MA, USA). Powdered samples
were placed on the conductive adhesive tape glued to the specimen mount and measured in a holder
for non-conductive samples. The acceleration voltage was equal to 10 kV. The stream of argon was
used to remove the powder loosely bounded to the tape before the measurement.
2.2.3. Laser Diffraction Measurements
A Malvern Mastersizer 3000 (Malvern, UK) equipped with a HydroEV unit was used to determine
particle size distribution. The samples were analyzed by the wet method using cyclohexane (reflective
index, RI = 1.426) as a dispersant. Fraunhofer diffraction theory was applied to find the relationship
between the particle size and the light intensity distribution pattern. The reported data represents the
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medians (D50 values) calculated as averages from ten series of measurements of each sample and the
distribution span.
2.2.4. Powder X-Ray Diffraction (PXRD)
The diffraction patterns of the samples, i.e., pure substances, solid dispersions, and tablets, were
registered at ambient temperature using an X-ray Rigaku Mini Flex II diffractometer (Tokyo, Japan) with
a 5◦/min step. Samples were scanned from 3◦ to 45◦. Monochromatic Cu Kα radiation (λ = 1.5418 Å)
was used.
2.2.5. Differential Scanning Calorimetry (DSC)
The thermal properties of the solid dispersions, raw bicalutamide, and carriers were examined
using a differential scanning calorimetry (DSC) 1 STARe System (Mettler-Toledo, Greifensee,
Switzerland). The measuring device was equipped with an HSS8 ceramic sensor with 120 thermocouples
and a liquid nitrogen cooling station. The instrument was calibrated for temperature and enthalpy
using zinc and indium standards. The glass transition temperature, crystallization, and melting were
determined as the midpoint of the glass transition step, the onset of the exothermic peak, and the
peak of the endothermic event, respectively. The samples were measured in an aluminum crucible
(40 µL). The sample mass used for DSC experiments varied between 7 to 10 mg. All measurements
were carried out with and without annealing (T = 323 K; t = 10 min). The experiments were performed
from 273 to 478 K, with a heating rate equal to 10 K/min.
2.2.6. Preparation of Tablet Blends
The composition of each three formulations containing raw BCL or solid dispersions are presented
in Section 3.3. Bicalutamide or solid dispersions were manually mixed with excipients: cellulose
microcrystalline as a filler for 3 min, sodium starch glycolate as a disintegrant for 3 min and magnesium
stearate as a lubricant for 1 min, in the porcelain dish.
2.2.7. Tableting Process and Tablet Characterization
The compression of tablets blends was performed using a single punch tableting machine
(Korsch EK0, Berlin, Germany) equipped with the round flat punches which are 8 mm in diameter;
each tablet type contained 50 mg of the active substance. Punches were equipped with tensiometers
connected to a computer by Esam Traveler 1 Data Acquisition System Master Unit, type 0508-S-ESA
(ESA Messtechnik GmbH, München, Germany). To obtain tablets that possess satisfactory properties,
the pressure force applied on a blend containing raw bicalutamide and solid dispersions was equal to
7 kN (140 MPa) and 2 kN (40 MPa), respectively.
The mass uniformity of tablets was measured based on the method described in European
Pharmacopoeia (Ph. Eur.) 9.0. The hardness, thickness and diameter of 20 randomly selected tablets
were measured using hardness tester apparatus (VanKel VK200, Agilent Technologies, Santa Clara, CA,
USA) and expressed as a mean value with standard deviation. The friability test was performed using
a Pharma Test apparatus (Pharma Test Apparatebau AG, Hainburg, Germany). The disintegration
time of the tablets was measured in distilled water at 37 ◦C using an Electrolab ED-2 SAPO (Electrolab,
Mumbai, India) disintegration apparatus at 30 strokes/min.
2.2.8. Dissolution Studies
The dissolution studies were carried out using the method recommended by the Food and Drug
Administration (FDA) for BCL tablets, i.e., United States Pharmacopeia (USP) paddle apparatus
(II type), and the parameters, i.e., 50 rpm, 1000 mL of 1% SLS solution, 37 ± 0.5 ◦C. The analysis was
performed in a Vision Elite 8 apparatus (Hanson Research, Chatsworth, CA, USA) equipped with a
Vision G2 AutoPlus Autosampler, and an AutoFill sample collector (Hanson Research, Chatsworth,
Materials 2020, 13, 2848 5 of 14
CA, USA). Samples, i.e., raw BCL, physical mixture, and solid dispersions obtained by supercritical
carbon dioxide methods, containing the equivalent of 50 mg of the active substance, as well as prepared
tablets, were poured into the beakers. A volume of 5 mL of the samples was withdrawn from each
dissolution vessel at predefined intervals, filtered, diluted, and assayed spectrophotometrically at
λ = 272 nm (UV-1800 Shimadzu, Shimadzu Corporation, Kyoto, Japan). After the collection of each
sample, the dissolution medium was replaced with the same volume of pure one. The tests were
carried out in triplicate, and the results represent averages with their standard deviations.
2.2.9. Contact Angle Measurements
A DSA255 drop shape analyzer (Krüss, Hamburg, Germany) was used to measure the contact
angles using a sessile drop technique. A droplet of distilled water of volume equal to 2 µL was
deposited on the surface of prepared tablets.
2.2.10. Stability Studies
Tablets were packed into PVC/Al blisters and placed in climate chambers (Memmert
GmbH + Co. KG, Schwabach, Germany) and stored in either 25 ◦C/60% relative humidity (long-term
conditions) or 40 ◦C/75% relative humidity (accelerated conditions). After six-month storage, tablets
were analyzed for the following parameters: mass, hardness, thickness, contact angle, and dissolution
rate of bicalutamide. The solid dispersion was analyzed after its preparation. The tablets’ properties
were evaluated just after the preparation and after the stability studies.
3. Results and Discussion
3.1. Solid-State Characteristics of Solid Dispersions
Based on the SEM results (Figure 1), raw bicalutamide exhibited elongated crystals of smooth
surfaces. They were hexagonal and 30–160 µm long (Figure 1A). The median of the particle size
distribution determined using a laser diffraction measurements laid was 81.7 µm (Table 1). The analysis
of microphotographs of carriers indicated that Macrogol 6000 exhibited irregular particles of smooth
surface and length not exceeding 100 µm (Figure 1B). In the case of the particles of Poloxamer® 407, they
were smooth and spherical, of a diameter varying between 50 µm and 250 µm (Figure 1C). The medians
of the particle size were 113 µm and 180 µm for PEG6000 and PLX407, respectively (Table 1). However,
the distribution span for PEG6000 was much higher than for the other compounds, which indicated a
wide distribution. The analysis of the particle size distribution revealed the presence of dust particles
in each sample visible as a distribution tail within the region below 10 µm (Figure 2). In the case of
bicalutamide and PLX407 the distributions were narrow and symmetrical (despite said tails), while
in the case of Macrogol, the particle size was distributed uneven, with a maximum shift towards big
particles. The distribution curve is skewed to the left, which can explain the differences between the
size calculated from the SEM picture and laser diffraction measurements. The particles visualized
using an electron microscope represent the fraction described by the extended distribution shoulder
visible on the left side of the plot (pictures showing greater particles at the same magnification were not
representative enough and are not presented here), while the laser diffraction assessed all the particles
present in the sample.
After the treatment of BCL-PEG6000 binary mixtures by a supercritical carbon dioxide at 130 bar
and 50 ◦C in the high-pressure reactor, solid dispersions were pulverized and white, free-flowing
powders were obtained. In the case of solid dispersion with Poloxamer® 407, prepared at higher
process parameters, i.e., pressure 140 bar, temperature 60 ◦C. The obtained sample also was white;
however, its structure was foamy. After pulverized, white, free flowing powder was obtained.
Solid dispersions morphology was analyzed using SEM. The obtained results showed that the
sample containing Macrogol 6000 exhibited irregular particles of a smooth surface with well-visible
incorporated particles of different contrast. They were identified as the crystals of the active substance
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(Figure 1D). The particles of the solid dispersion with Poloxamer® 407 were rough, with visible
inclusions of BCL crystals (Figure 1E).
Table 1. Particles size distribution of raw bicalutamide and carriers, results obtained by the laser
diffraction method.
Substance D50 (µm) Span
Bicalutamide 81.7 1.70
Macrogol 6000 113.0 3.18
Poloxamer® 407 180.0 2.02
BCL-PEG6000 1120 2.01
BCL-PLX407 356 2.90Materials 2020, 13, x FOR PEER REVIEW 6 of 15 
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Figure 1. SEM image of raw bicalutamide (A), PEG6000 (B), PLX407 (C), BCL-PEG6000, (D) and
BCL-PLX407 (E) solid dispersions.
The laser diffraction measurements revealed that solid dispersions exhibited a wide particle
size distribution, in both cases skewed to the left, with two visible modes (Figure 2). The median of
BCL-PEG6000 solid dispersion particles lay above 1 mm, which could be a result of the intense laser
light diffraction on big particles and the presence of a well-resolved mode of the distribution curve.
In the case of solid dispersion with Poloxamer® 407, the median of the particle size distribution was
equal to 356 µm (Figure 2).
The thermal properties were obtained using differential scanning calorimetry (DSC). The presence
of an endothermic peak with an onset at 196 ◦C corresponds to the melting temperature of form
I polymorph of bicalutamide (Figure 3). After the treatment with supercritical CO2, decreases in
bicalutamide crystallinity in both obtained solid dispersions were noticed. This was confirmed by a
decrease in the melting temperature of the active substance. For the solid dispersion prepared with
Macrogol 6000, the melting of bicalutamide was recorded as an onset at 152.6 ◦C. The presence of the
second endothermic peak with the onset at 60 ◦C corresponds to the melting point of the carrier. In the
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case of solid dispersions with Poloxamer® 407, the glass transition temperature was recorded at−6.2 ◦C.
Bicalutamide crystallization occurred at 145.4 ◦C, while it melted at 167.4 ◦C. This indicated that the
treatment with supercritical CO2 led to drug amorphization. However, the system was characterized
by very low physical stability in ambient conditions, expressed as a negative value of Tg. It resulted
from low values of PLX407 Tg, −65 ◦C, combined with Tg of amorphous form of bicalutamide equal to
55 ◦C [36,37].
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The molecular structure of each compound and solid dispersions was assessed using X-ray
diffractometry. The diffraction pattern of raw bicalutamide is characteristic for crystalline form I
polymorph, rich in distinctive Braggs peaks at 2θ equal to 6.2◦, 9.5◦, 12.3◦, 14.3◦–14.6◦, 17.0◦, 19.0◦,
20.0◦, and 24.0◦ (Figure 4). In the case of the used carriers, the diffraction patterns showed only two
signals for each component, resulting from the semi-crystalline nature of the polymers. A decrease
in the drug crystallinity was noticed in both types of solid dispersions. It was demonstrated by the
decrease in the intensity and broadening of the peaks (Figure 4). Interestingly, the positions of the
peaks shifted in comparison with the initial form of the drug. This indicated the recrystallization
into the second polymorph of BCL, with the Braggs peaks positioned at 12.8◦, 17.4◦, 19.5◦, 23.7–24.3◦,
and 25.4◦ [27].
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Figure 4. X-ray diffraction of raw bicalutamide and carriers, i.e., Macrogol 6000 and Poloxamer® 407,
and solid dispersions.
ide Dis olution
preparati of solid dispersions using the supercritical rbon dioxide method with Macrogol
6000 and Polox mer®407 led to a decrease in bicalutamide crystallinity, which resulted in dissolution
improvement. The dissolution profiles of bicalutamide were very similar in both types of solid
dispersions (Figure 5). After 1 h, 74.80 ± 1.66% of the drug dissolved from BCL-PEG6000 solid
dispersion, and 77.43 ± 6.01% from the BCL-PLX407 one. The amount of bicalutamide dissolved
from solid dispersions was approximately nine times greater than that determined for crystalline
bicalutamide (form I polymorph), as 8.85 ± 1.02% of pure drug dissolved. No significant differences in
the drug dissolution characteristics were noticed after the physical mixing of the active substance with
any of the two polymers (approximately 12% of drug dissolved from each mixture). This confirms
that the hydrophilic character of the carriers was not a crucial factor driving drug dissolution, and the
dissolution improvement was related to the changes that occurred after the treatment with supercritical
CO2. During the process, the drug substance was dissolved in the polymer in supercritical CO2,
and the magnetic stirrer ensured uniform mixing of the ingredients. In the process of carbon dioxide
removal, the sample solidified as a result of the rapid decrease in pressure. It provided homogenous
distribution of the drug substance in the carrier.
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3.3. Characteristics of Tablets Containing BCL-PEG6000, BCL-PLX407 Solid Dispersions and Raw BCL
The three types of tablets were prepared using the direct compression method. The BCL-PEG6000
and BCL-PLX407 solid dispersions and raw bicalutamide were mixed with cellulose microcrystalline,
sodium starch glycolate, and magnesium stearate to formulate tablets (Table 2). The obtained results
revealed that hardness, thickness and friability were satisfactory.
Table 2. The composition of tablets containing BCL-PEG6000 and BCL-PLX407 solid dispersions and
raw bicalutamide.
Substance
Tablets
Raw BCL
Solid Dispersion
BCL-PEG6000 BCL-PLX407
Content of Compounds in One Tablet
mg % mg % mg %
BCL 50.00 41.67 - - - -
BCL-Polymer (SD) - - 100.00 58.82 100.00 58.82
Cellulose - - -
37.65 64.00 37.65Microcrystalline 64.00 53.33 64.00
Sodium starch glycolate 4.80 4.00 4.80 2.82 4.80 2.82
Magnesium stearate 1.20 1.00 1.20 0.71 1.20 0.71
The analysis of hardness showed that the tablets containing solid dispersions were characterized by
higher hardness than those with raw bicalutamide (Table 3). This resulted from the binding properties
of the used carriers, which also affected the disintegration time. Tablets containing solid dispersions
disintegrated for longer than tablets with raw bicalutamide. Moreover, the tablets with BCL-PLX407
solid dispersion exhibited a six-fold longer disintegration time than those with BCL-PEG6000 solid
dispersion, 24 min 22 s and 4 min 23 s, respectively. The difference was caused by the properties of
poloxamer, which behaves like a binding substance [38]. During the compression process, particles
tend to aggregate and increase the number of direct contact points between them, which extends
tablet disintegration. Despite the surface activity and solubilizing activity of the polymer, a great
content of poloxamer in the sample can retard tablet disintegration due to the gelling properties of the
polymer [38–40].
Table 3. The properties of tablets containing solid dispersions (SD) and crystalline bicalutamide.
System
Parameter Mass (mg) Thickness
(mm)
Hardness
(kp)
Friability
(%)
Disintegration
Time (min:s)
Contact
Angle (◦)
SD BCL-PEG6000 169.3 ± 7.0 3.60 ± 0.04 2.87 ± 0.63 0.0 4:23 50.8
SD BCL-PLX407 168.1 ± 5.8 3.43 ± 0.04 2.28 ± 0.64 0.4 24:22 55.8
Raw BCL 121.5 ± 3.6 2.08 ± 0.04 1.97 ± 0.25 0.6 00:31 85.4
The use of hydrophilic polymers in solid dispersion resulted in an increase in the wettability of
the surface in comparison with the tablets containing raw bicalutamide. The tablets containing solid
dispersions were more hydrophilic. They exhibited lower values of contact angles than the tablets
with crystalline BCL:50.8◦ and 55.8◦ for the tablets containing PEG6000 and PLX407, respectively.
The X-ray diffraction analysis indicated that the active substance was amorphous. The presence of
a broad halo instead of the Braggs peaks characteristic for crystalline drug substances, visible in Figure 4,
indicated that bicalutamide was amorphous in all tested tablets (Figure 6). We assumed that this resulted
from the propensity of bicalutamide to undergo activation upon mechanical treatment [10,12,27].
This means that the material gains some amount of energy which needs to be released. The relaxation
Materials 2020, 13, 2848 10 of 14
of the stress field, applied during compression, occurs in several ways, including amorphization, as in
the case of investigated tablets.
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Figure 6. Diffraction patterns of tablets containing raw bicalutamide and solid dispersions.
As shown in Figure 7, bicalutamide release from the tablets indicated that the use of solid
dispersions in tablets significantly enhanced drug release. This resulted from the improved wettability
and amorphization of bicalutamide upon compression. After 1 h, 80.16± 8.56% and 56.61± 4.84% of the
drug released from the tablets with PEG6000 and PLX407 solid dispersions, respectively. From tablets
containing raw bicalutamide, 17.99 ± 1.70% dissolved, which was two times greater in comparison with
the drug alone. Although the dissolution of bicalutamide from both solid dispersions was comparable
at each time point, the differences in profiles were noticeable between solid dispersions (Figure 5) and
corresponding tablets. After 30 min, 28% more bicalutamide was dissolved from tablets containing
BCL-PEG6000 solid dispersion in comparison with the BCL-PLX407 tablets.Materials 2020, 13, x FOR PEER REVIEW 11 of 15 
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properties of the tablets (Table 4) in comparison with tablets analyzed immediately after preparation
(please refer to Table 3).
Table 4. Properties of tablets after six months of storage.
System
Parameter Mass (mg) Hardness
(kp)
Thickness
(mm)
Disintegration Time
(min:s)
Contact Angle
(◦)
25 ◦C, 60% RH
SD BCL-PEG 168.3 ± 3.5 2.47 ± 0.15 3.66 ± 0.01 04:57 48.9
SD BCL-PLX 174.5 ± 5.1 2.63 ± 0.51 3.53 ± 0.05 27:10 58.9
40 ◦C, 75% RH
SD BCL-PEG 177.0 ± 4.4 1.80 ± 0.36 3.73 ± 0.08 04:59 59.8
SD BCL-PLX 175.9 ± 5.5 1.25 ± 0.07 3.76 ± 0.06 14:39 53.8
In both types of tablets, drug release decreased after storage, regardless of the storage conditions
(Figure 8A,B). However, less noticeable changes occurred for tablets stored at 25 ◦C and 60% RH.
The amount of dissolved bicalutamide was 70.42% and 50.82% in the case of tablets containing solid
dispersion with PEG6000 and PLX407, respectively. On the contrary, 32.01% of bicalutamide was
released from BCL-PEG6000 tablets stored in accelerated conditions, which was a 2.5-fold decrease,
in comparison with the freshly prepared tablets.
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Figure 8. Release profiles of bicalutamide from tablets containing solid dispersion with either PEG6000
(A) or PLX4087 (B) after stability studies, in comparison with tablets analyzed after preparation.
Moreover, after the six-month stability studies, no phase transition of the drug substance occurred
(Figure 9). The diffraction patterns did not change in comparison with those measured for tablets
directly after compression (Figure 6). The bicalutamide remained amorphous, as confirmed by the
halo visible in the diffractograms (Figure 9). This indicated that water absorbed fro the air in the
climate chambers did not cause drug recrystallization.
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4. Conclusions
This study has examined the effect of supercritical carbon dioxide treatment on the properties
of binary systems containing bicalutamide and Macrogol 6000 or Poloxamer® 407. The dissolution
and attributes of tablets were evaluated. The scCO2 influenced not only the size and shape of the
particles of the processed substances, but also the dissolution characteristics of bicalutamide from solid
dispersions. Supercritical conditions induced a decrease in the crystallinity of the active substance.
The obtained solid dispersions were successfully formulated in tablets. The tableting process induced
the amorphization of the drug substance. This phenomenon confirmed the sensitivity of bicalutamide
on mechanical activation. After 1h, the amount of bicalutamide dissolved from tablets with PEG6000
remained unchanged. In the case of tablets containing Poloxamer®407, the amount of released
substance decreased by 20%. However, the compression affected the dissolution profiles of the drug
substance in comparison with solid dispersion. The stability studies indicated that storage conditions
affected the tablets’ properties. The amount of the released drug decreased regardless of the storage
conditions. However, in the stability studies after six months, the diffraction patterns did not change,
which indicated that the physical state of the active substance was unchanged.
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